Abstract. Background: n-ELAV (neuronal-Embryonic Lethal, Abnormal Vision)-like genes belong to a family codifying for onconeural RNA-binding proteins. Anti-Hu-antibodies (anti-Hu-Ab) are typically associated with paraneoplastic encephalomyelitis/sensory neuropathy (PEM/PSN), and low titres of anti-Hu-Ab, were found in newly diagnosed Small Cell Lung Cancer (SCLC). The aim of this study is to develop a sensitive and quantitative molecular real-time PCR assay to detect SCLC cells in peripheral blood (PB) through nELAV-like transcripts quantification.
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Introduction
ELAV-like proteins, also called Hu antigens, are a small family of RNA-binding proteins involved in the development and maintenance of nervous system [3, 19, 29] . Four ELAV-like proteins have been identified in the genomes of vertebrates, named ELAVL1 (HuR), ELAVL2 (HuB), ELAVL3 (HuC) and ELAVL4 (HuD), [16, 17, 22, 27] . HuR is expressed in all tissues examined [28] , whereas HuB, HuC and HuD are normally expressed only on terminally differentiated neurons [5, 17, 19] . These proteins are highly homologous in sequence and highly evolutionarily conserved. All four members of the family encode for RNA-binding proteins endowed with three RNA-interacting domains known as RRM (RNA recognition motif) [6] .
The human members of ELAV family are of particular interest since they are tumour antigens associated predominantly with SCLC. During the course of their disease, SCLC affected patients expresses some tissue-specific Hu antigens and develops antibodies against these proteins. The antibodies developed against these tumour antigens reach the brain were they induce an autoimmune inflammatory response resulting in paraneoplastic encephalomyelitis/sensory neuropathy (PEM/PSN) [2, 10] . Previous studies reported that low titres of anti-Hu-Ab on HuD, were also detected in 16-25% of newly diagnosed SCLC without PEM/PSN [8, 12, 20, 21] . SCLC of patients Hu-positive grow more indolently, suggesting that the expression of ELAV like proteins might be associated with a better disease prognosis [12] .
Several prospective studies have suggested that the detection of tumour cells in the bone marrow or peripheral blood of cancer affected patients may contribute for the determination of minimal residual disease and as prognostic marker for the development of distant metastases and overall survival [1, 13, 14] .
To date, Hu-positive SCLC patients are identified by serological identification of Hu proteins by using several techniques, immunohistochemistry, immunoblotting or enzyme linked immunosorbent assay (ELISA) of these proteins [7, 9, 11, 18] . Recently, a potential application of ELAVL4 real-time quantitative real-time PCR (qRT-PCR) for detection of disseminated neuroblastoma cells are described [26] . The use of this technique offers several advantages over conventional PCR in terms of time and reduction of contamination by using a closed amplification and detection system. The aim of this study was to develop and validate a quantitative RT PCR approach for the detection of HuB, HuC and HuD transcripts in peripheral blood (PB) of patients with small-cell lung cancer. Expression of nELAV gene was analyzed in 25 PB samples from patients with SCLC without PEM/PSN, collected at diagnosis. PB samples from 12 normal controls were included as negative controls.
Materials and methods

Patients and samples
A group of 13 male untreated SCLC patients with limited disease and 11 male and 1 female untreated patients with extensive disease SCLC, recruited at Internal Medicine Division of "Casa Sollievo della Sofferenza" Hospital, were enrolled in this study. All SCLC patients were diagnosed and staged according with the two stage system, introduced by the Veterans' Affairs Lung Study Group (VALSG) [4] . Peripheral blood samples taken at diagnosis were analysed.
Negative controls were blood samples of never smoking male healthy volunteers (n = 12) recruited at Transfusional Centre of "Casa Sollievo della Sofferenza" Hospital, who had no evidence of any clinically detectable disease at the time of blood withdrawal. For all individuals enrolled in this study a written informed consent was obtained.
For each patient 2.5 ml of peripheral blood were collected on PAX-gene™ Blood RNA Tubes (PreAnalytiX), stored at room temperature for a minimum of 2 hours, then at −20 • C for a minimum of 24 h, before processing or storing at −80 • C.
Sample processing, RNA extraction and cDNA synthesis
Total RNA was extracted using PAXgene Blood RNA kit (PreAnalytix). RNA was eluted in RNAse free-water and stored at −80 • C until used. RNA quality and concentration were measured by using 2100 Expert Analyzer (Agilent Technology) and only RNA with RIN (RNA Integrity Number) 7.0 was processed. After heating at 65 • C for 5 min in order to denature RNA and to inactivate RNases, 500 ng of total RNA was subjected to reverse transcription using the QuantiTect Reverse Transcription Kit (Qiagen). cDNA was synthesized according to the manufacturer's instructions. 
Taqman primers design
The set of primers designed with Primer Express 2.0 software (Applied Biosystems, Foster City, CA) were located in the 3 UTR of HuB, HuC and HuD genes respectively and are listed in Table 1 . The primers were designed to differentiate between the highly homologous n-ELAV-like genes (Suppl. Fig. 1 : http://www. qub.ac.uk/isco/JCO). Glyceraldehyde phosphate dehydrogenase (GAPDH) was chosen as housekeeping gene, and commercially available primers were used (see the User Bulletin #2, Applied Biosystems, for the primers sequences).
Plasmids construction, amplification and purification
PCR fragments for all three n-ELAV-like genes and GAPDH as control gene were generated by using primers listed in Table 1 , were cloned in the pCR ® 4-TOPO ® Vector (Invitrogen) and introduced in Escherichia coli DH5α™. Plasmid DNA from the selected transformant cells was isolated by using the QIAprep ® Spin Miniprep Kit (Qiagen). Recombinant vectors, linearised with Not I, were serially diluted. Five plasmid dilutions of pCR ® 4-TOPO ® -HuB, pCR ® 4-TOPO ® -HuC, pCR ® 4-TOPO ® -HuD, pCR ® 4-TOPO ® -GAPDH (in the range of 1 × 10 6 copies to ten copies) were used to construct the standard curves for real-time PCR.
Taqman quantitative real-time PCR (qRT-PCR) conditions
SYBR Green amplification mixture (10 µl) contained 2.5× QuantiTect™ SYBR Green PCR Master Mix (Qiagen), 250 nM of each forward and reverse primers and 1 µl of template cDNA or plasmid product (serial dilutions). Reactions were run on ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). Cycling conditions were as follows: 10 min at 95 • C, 40 cycles at 95 • C for 15 s and 60 • C for 60 s. Each assay was carried out in triplicate and the transcription level was normalized using GAPDH as reference gene. A standard curve (used as calculation method) with five plasmid dilutions of pCR ® 4-TOPO ® -HuB, pCR ® 4-TOPO ® -HuC, pCR ® 4-TOPO ® -HuD, pCR ® 4-TOPO ® -GAPDH was included in each respective PCR run. Calibration curves were constructed by plotting the threshold cycle versus logarithm of the relative copy number.
qRT-PCR data analysis
Crossing points (beginning of the PCR exponential phase) were assessed by the second derivate maximum algorithm and plotted against the concentrations of the standards. Sample concentration was calculated using the plasmid standard curve, resulting in plasmid concentrations expressed as copy number of corresponding standard molecules. The relative sample amount was expressed as ratio marker (n-ELAV-like/GAPDH).
Statistics
nELAV mRNA expression in healthy blood donors and cancer patients were compared by using the Mann-Whitney U -test (for unpaired non-normally distributed groups) followed by a normal approximation with continuity correction. Values of P < 0.05 were considered statistically significant.
Sensitivity of the qPCR assays
To establish quantitative range and main detection limit, 10-fold serial dilutions of plasmid containing HuD, HuC or HuB insert were analyzed in triplicate by qRT-PCR (Suppl. Fig. 2 : http://www.qub.ac.uk/isco/ JCO). For all three target genes we were able to detect as low as ten plasmid copies, although accurate quantification requires at least 100 plasmid copies. The dynamic range for quantification using plasmid calibration curves was six orders of magnitude for all three markers.
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Results
Expression of nELAV markers in healthy volunteers
HuB, HuC and HuD expression was evaluated in PB samples from 12 healthy blood donors (HBD). For HuD and HuB a median target genes/GAPDH copy number ratio of 0 (95% confidence interval, CI 0-30) and 0 (95% CI 0-3, HuB) were detected respectively. Whereas for HuC a median target genes/GAPDH copy number ratio of 26 (95% CI 0-73) was found.
Expression of nELAV markers in SCLC patients
To determine HuB, HuC and HuD expression in SCLC patients, 25 peripheral blood samples from affected individuals were analyzed. A statistically significant difference in target genes/GAPDH copy number ratio was found for HuD (median 1; 95% CI 0-25) and HuB (median 4; 95% CI 0-25) as compared with healthy blood donors (P 0.00034 and P 0.00001, respectively). For HuC the median target genes/GAPDH copy number ratio was 2 (95% CI 0-26) and no statistically significant differences were detected as compared with levels of mRNA expression in healthy blood donors (P = 0.24257).
Since low levels of nELAV expression were detected for all three markers in samples from healthy blood donors, a cut-off value for the target genes/GAPDH copy number ratio was introduced to distinguish between normal and pathological samples. These cut-off values were calculated as the upper limit of the 95% CI of the distribution of the target gene/GAPDH copy number ratios in blood samples from healthy blood donors and were set as follows HuD > 30, HuB > 3, HuC > 73 (Fig. 1) . Six out of the twenty-five Table 2 Correlation between patient characteristics and HuD, HuB and HuC positiveness of SCLC patients (n = 25) Samples HuD HuB HuC Metastasis Status
SCLC patients were positive for HuD expression (24% (6/25), 13 were positive for HuB expression (52%) and only 4 showed HuC expression (16%) ( Table 2) . Concomitant positiveness of HuD and HuB was detected in 5 of the 25 pathological samples (20%). In total 14 out of the 25 SCLC peripheral blood samples (56%) displayed positive expression of HuD, HuB or both. Among these 70% (9/13) of patients showed limiteddisease stage in comparison with 34% (4/12) with extensive disease. Only one HuD and HuB-positive patients had brain metastases at the time of diagnosis (Table 2).
Discussion
The high sensitivity of qRT-PCR assays for detecting mRNA expression of tumour associated antigens has led, in the last few years, to a large number of studies aimed to use these technique for the definition of minimal residual disease and as prognostic indicator.
The main advantage of real-time techniques is the ability of detecting one tumour cell in one million normal peripheral blood cells, which is at least 10 times more sensitive than immunohistochemistry [23] with a detection limit of one tumour cell/10 6 -10 8 normal cells [24] [25] [26] . A further advantage of quantitative PCR is the possibility to take into account variations in RNA and/or cDNA amount by quantifying housekeeping genes and subsequent normalization of marker concentration to that of the housekeeping gene.
In this study, a quantitative qRT-PCR method was applied to detect SCLC cells in peripheral blood of patients with SCLC by using nELAV genes as tumour markers. nELAV genes play an essential role in the development of nervous system and is highly expressed in neuroendocrine tumours, such as SCLC [7] . In addition auto-antibodies against Hu-proteins could be detected in serum of patients affected by this tumour type [8, 12, 20] .
Recently, the detection of HuD transcript by qRT-PCR was reported as molecular marker for the definition of MRD (minimal residual disease) in neuroblastomas patients [26] . To the best of our knowledge the use of this technique to investigate on HuB and HuC and HuD expression in SCLC has not been previously reported.
We first assessed nELAV expression in the peripheral blood samples of a group of 12 healthy blood donors.
Since low level of expression was detected in this group of individuals for all three genes, cut off value was established to distinguish normal and pathological samples. These value was set at the upper limit of the 95% CI of the median of control group, thus a SCLC affected patients analyzed was considered positive for the expression of the nELAV mRNA when exceeding this value. Twenty-four percent, 52% and 16% of samples scored positive for HuD, HuB and HuC respectively, whereas the 20% of samples show concordant results for both HuD and HuB markers.
Overall 56% of the tumour analyzed showed HuD or HuB transcript above the cut-off values.
The rate of HuB positiveness patients in limited disease (70%) seems to be different from those with extensive disease (34%), but a prospective study of disease evolution in patients with limited disease is needed to confirm if the HuB and/or HuD expression in peripheral blood may reflect a specific level of diffusion and aggressive form in this tumour type. The detection and quantification of nELAV transcripts in peripheral blood is assured over a wide concentration range down to 10 standard molecules and qRT-PCR as-say for the three nELAV mRNA showed a sensitivity of detecting one tumour cell among 10 6 normal peripheral blood mononuclear cells, which is in accordance with previous reports. Moreover, the use of plasmid dilutions for quantification assure a more reproducible and accurate quantifications of gene expression than dilutions based on cell lines [15] since the variation between different PCR runs is extremely low and absolute copy numbers can be calculated based on concentration measurements.
In summary, our qRT-PCR experiments indicate that the combined detection of HuB and HuD transcript by absolute quantification is able to detect more than half of the patients affected by SCLC. The high sensitivity of this technique could be particularly useful for monitoring the disease after treatment and for the detection of minimal residual disease in SCLC patients with an apparent complete response to therapy. However, additional studies with larger patients groups are required to confirm these experimental observations.
